• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在蛋白酶激活受体1存在或不存在的情况下,蛋白酶激活受体4利用阴离子残基与α-凝血酶相互作用。

Protease-activated receptor 4 uses anionic residues to interact with alpha-thrombin in the absence or presence of protease-activated receptor 1.

作者信息

Nieman Marvin T

机构信息

Division of Hematology/Oncology, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106-7284, USA.

出版信息

Biochemistry. 2008 Dec 16;47(50):13279-86. doi: 10.1021/bi801334s.

DOI:10.1021/bi801334s
PMID:19053259
Abstract

Thrombin activates protease-activated receptor 1 (PAR1) faster than protease-activated receptor 4 (PAR4) due to a hirudin-like sequence in the exodomain of PAR1 that binds thrombin's exosite I. However, recombinant exodomain studies indicate that PAR4 does have extended contacts with alpha-thrombin that influence PAR4's kinetics of cleavage. In this report, the role of an anionic cluster (Asp(57), Asp(59), Glu(62), and Asp(65)) in the exodomain of PAR4 is examined for its influence on cleavage and activation of PAR4 on cells in the absence or presence of PAR1. Alpha-thrombin induces wild-type PAR4 (PAR4-wt) calcium flux with an EC(50) of 110 nM, whereas mutation of the four anionic residues (PAR4-AAAA) increases the EC(50) to 641 nM. In contrast, PAR4-wt and PAR4-AAAA are activated by gamma-thrombin with similar EC(50) values (588 and 449 nM, respectively; p = 0.48), suggesting a role for alpha-thrombin's exosite I in PAR4 activation. Coexpression of PAR1 lowered the EC(50) of cleavage for PAR4-wt from 321 to 26 nM and for PAR4-AAAA from 1.5 microM to 360 nM. Individual point mutations at Asp(57), Asp(59), Glu(62), and Asp(65) show that PAR4-D57A is activated by alpha-thrombin with the same EC(50) as PAR4-wt (140 nM) whereas PAR4-D59A is the same as PAR4-AAAA (699 nM). Glu(62) and Asp(65) contribute to alpha-thrombin recognition, but to a lesser extent. This report shows that PAR4 uses its anionic cluster to interact with alpha-thrombin and that this interaction is important even in the presence of PAR1.

摘要

由于蛋白酶激活受体1(PAR1)胞外域中存在一个与凝血酶外位点I结合的水蛭素样序列,凝血酶激活PAR1的速度比蛋白酶激活受体4(PAR4)快。然而,重组胞外域研究表明,PAR4确实与α-凝血酶有广泛的接触,这影响了PAR4的裂解动力学。在本报告中,研究了PAR4胞外域中一个阴离子簇(Asp(57)、Asp(59)、Glu(62)和Asp(65))在不存在或存在PAR1的情况下对PAR4在细胞上的裂解和激活的影响。α-凝血酶诱导野生型PAR4(PAR4-wt)钙通量,EC(50)为110 nM,而四个阴离子残基的突变(PAR4-AAAA)使EC(50)增加到641 nM。相比之下,PAR4-wt和PAR4-AAAA被γ-凝血酶激活,EC(50)值相似(分别为588和449 nM;p = 0.48),表明α-凝血酶的外位点I在PAR4激活中起作用。PAR1的共表达将PAR4-wt的裂解EC(50)从321 nM降低到26 nM,将PAR4-AAAA的裂解EC(50)从1.5 μM降低到360 nM。在Asp(57)、Asp(59)、Glu(62)和Asp(65)处的单个点突变表明,PAR4-D57A被α-凝血酶激活的EC(50)与PAR4-wt相同(140 nM),而PAR4-D59A与PAR4-AAAA相同(699 nM)。Glu(62)和Asp(65)有助于α-凝血酶的识别,但程度较小。本报告表明,PAR4利用其阴离子簇与α-凝血酶相互作用,并且即使在存在PAR

相似文献

1
Protease-activated receptor 4 uses anionic residues to interact with alpha-thrombin in the absence or presence of protease-activated receptor 1.在蛋白酶激活受体1存在或不存在的情况下,蛋白酶激活受体4利用阴离子残基与α-凝血酶相互作用。
Biochemistry. 2008 Dec 16;47(50):13279-86. doi: 10.1021/bi801334s.
2
Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage.蛋白酶激活受体-4利用双脯氨酸和一个阴离子保留基序来识别和裂解凝血酶。
Biochem J. 2003 Dec 15;376(Pt 3):733-40. doi: 10.1042/BJ20030954.
3
Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site.凝血酶在凝血酶裂解位点与蛋白酶激活受体1(PAR1)和蛋白酶激活受体4(PAR4)的相互作用。
Biochemistry. 2007 Jul 24;46(29):8603-10. doi: 10.1021/bi700597p. Epub 2007 Jun 27.
4
Mapping the interaction of bradykinin 1-5 with the exodomain of human protease activated receptor 4.绘制缓激肽1-5与人蛋白酶激活受体4胞外域的相互作用图谱。
FEBS Lett. 2005 Jan 3;579(1):25-9. doi: 10.1016/j.febslet.2004.11.041.
5
Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy.纤溶酶对蛋白酶激活受体1(PAR1)凝血酶受体的脱敏作用:动力学、截短位点及其对溶栓治疗的意义。
Biochemistry. 1999 Apr 6;38(14):4572-85. doi: 10.1021/bi9824792.
6
Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by α-thrombin.蛋白酶激活受体 1(PAR1)和 PAR4 异二聚体是 α-凝血酶增强 PAR4 裂解所必需的。
J Biol Chem. 2013 Nov 8;288(45):32553-32562. doi: 10.1074/jbc.M113.472373. Epub 2013 Oct 4.
7
Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.通过分隔的环核苷酸作用对人血小板中蛋白酶激活受体(PAR)1和PAR4信号传导的调节
J Pharmacol Exp Ther. 2007 Aug;322(2):778-88. doi: 10.1124/jpet.107.121830. Epub 2007 May 24.
8
Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development.通过蛋白酶激活受体4(PAR4)的血小板活化参与凝血酶生成的起始过程以及血凝块弹性的形成。
Thromb Haemost. 2007 Mar;97(3):417-24.
9
Protease-activated receptor mediated RhoA signaling and cytoskeletal reorganization in LNCaP cells.蛋白酶激活受体介导的LNCaP细胞中的RhoA信号传导和细胞骨架重组。
Biochemistry. 2003 Jan 28;42(3):702-9. doi: 10.1021/bi027100x.
10
Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis.蛋白酶激活受体(PAR1和PAR2)有助于肿瘤细胞的运动和转移。
Mol Cancer Res. 2004 Jul;2(7):395-402.

引用本文的文献

1
A mouse model of the protease-activated receptor 4 Pro310Leu variant has reduced platelet reactivity.蛋白酶激活受体4 Pro310Leu变体的小鼠模型血小板反应性降低。
J Thromb Haemost. 2024 Jun;22(6):1715-1726. doi: 10.1016/j.jtha.2024.03.004. Epub 2024 Mar 19.
2
Protease-activated receptors in health and disease.蛋白酶激活受体在健康和疾病中的作用。
Physiol Rev. 2023 Jan 1;103(1):717-785. doi: 10.1152/physrev.00044.2021. Epub 2022 Jul 28.
3
The domino effect triggered by the tethered ligand of the protease activated receptors.
由蛋白酶激活受体的连接配体引发的级联反应。
Thromb Res. 2020 Dec;196:87-98. doi: 10.1016/j.thromres.2020.08.004. Epub 2020 Aug 4.
4
Molecular basis for activation and biased signaling at the thrombin-activated GPCR proteinase activated receptor-4 (PAR4).血栓激活的 G 蛋白偶联受体蛋白酶激活受体-4(PAR4)的激活和偏向信号转导的分子基础。
J Biol Chem. 2020 Feb 21;295(8):2520-2540. doi: 10.1074/jbc.RA119.011461. Epub 2019 Dec 31.
5
Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases.血小板信号转导与疾病:血栓及其他相关疾病的靶向治疗。
Pharmacol Rev. 2018 Jul;70(3):526-548. doi: 10.1124/pr.117.014530.
6
Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy.蛋白酶激活受体 4(PAR4):抗血小板治疗的有前途靶点。
Int J Mol Sci. 2018 Feb 14;19(2):573. doi: 10.3390/ijms19020573.
7
Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent.凝血酶诱导的足细胞损伤是蛋白酶激活受体依赖性的。
J Am Soc Nephrol. 2017 Sep;28(9):2618-2630. doi: 10.1681/ASN.2016070789. Epub 2017 Apr 19.
8
Identification of the minimum PAR4 inhibitor pharmacophore and optimization of a series of 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazoles.最小PAR4抑制剂药效团的鉴定及一系列2-甲氧基-6-芳基咪唑并[2,1-b][1,3,4]噻二唑的优化。
Bioorg Med Chem Lett. 2016 Nov 15;26(22):5481-5486. doi: 10.1016/j.bmcl.2016.10.020. Epub 2016 Oct 11.
9
Protease-activated receptors in hemostasis.止血过程中的蛋白酶激活受体。
Blood. 2016 Jul 14;128(2):169-77. doi: 10.1182/blood-2015-11-636472. Epub 2016 Apr 28.
10
Development and characterization of monoclonal antibodies against Protease Activated Receptor 4 (PAR4).抗蛋白酶激活受体4(PAR4)单克隆抗体的研制与特性分析
Thromb Res. 2015 Jun;135(6):1165-71. doi: 10.1016/j.thromres.2015.03.027. Epub 2015 Apr 9.